Compare ATCH & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ATCH | MDXH |
|---|---|---|
| Founded | 2022 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5M | 41.1M |
| IPO Year | 2024 | 2021 |
| Metric | ATCH | MDXH |
|---|---|---|
| Price | $0.21 | $0.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.00 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $84.47 | $30.78 |
| Revenue Next Year | $39.32 | $18.31 |
| P/E Ratio | $4.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.51 |
| 52 Week High | $1.92 | $5.33 |
| Indicator | ATCH | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 14.37 |
| Support Level | $0.21 | $0.51 |
| Resistance Level | $0.24 | $3.78 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 50.35 | 15.49 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.